Dual suppression of hemangiogenesis and lymphangiogenesis by splice‐shifting morpholinos targeting vascular endothelial growth factor receptor 2 (KDR). Issue 1 (20th September 2012)

• Record Type: Journal Article
• Authors: Uehara, Hironori; Cho, YangKyung; Simonis, Jackie; Cahoon, Judd; Archer, Bonnie; Luo, Ling; Das, Subrata K.; Singh, Nirbhai; Ambati, Jayakrishna; Ambati, Balamurali K.
• Is Part Of: FASEB journal. Volume 27:Issue 1(2013)
• Page Start: 76
• Page End: 85
• Publication Date: 2012-09-20
• Subjects: alternative polyadenylation -- corneal graft rejection; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.12-213835
• Languages: English
• ISSNs: 0892-6638

Abstract

Abstract : The KDR gene, which participates in angiogenesis and lymphangiogenesis, produces two functionally distinct protein products, membrane‐bound KDR (mbKDR) and its isoform, soluble KDR (sKDR). Since sKDR does not have a tyrosine kinase domain and does not dimerize, it is principally an antagonist of lymphangiogenesis by sequestering VEGF‐C. Alternative polyadenylation of exon 30 or intron 13 leads to the production of mbKDR or sKDR, respectively, yet the regulatory mechanisms are unknown. Here we show that an antisense morpholino oligomer directed against the exon 13‐intron 13 junction increases sKDR (suppressing lymphangiogenesis) and decreases mbKDR (inhibiting hemangiogenesis). The latent polyadenylation site in intron 13 of KDR is activated by blocking the upstream 5′ splicing site with an antisense morpholino oligomer. Intravitreal morpholino injection suppressed laser choroidal neovascularization while increasing sKDR. In the mouse cornea, subconjunctival injection of the morpholino‐inhibited corneal angiogenesis and lymphangiogenesis, and suppressed graft rejection after transplantation. Thus, this morpholino can be used for concurrent suppression of hemangiogenesis and lymphangiogenesis. This study offers new insight into the mechanisms and potential therapeutic modulation of alternative polyadenylation.—Uehara, H., Cho, YK., Simonis, J., Cahoon, J., Archer, B., Luo, L., Das, S. K., Singh, N., Ambati, J., Ambati, B. K. Dual suppression of hemangiogenesis and lymphangiogenesis by splice‐shifting morpholinos targeting vascular endothelial growth factor receptor 2 (KDR). FASEB J. 27, 76–85 (2013). www.fasebj.org